How to reach us

State Development Corporation of Thuringia mbH (LEG Thüringen)

Mainzerhofstraße 12 | 99084 Erfurt Germany
Phone: +49 361 5603-0
Write an Email

Rental enquiry

Innovative therapy platforms and biomimetics for personalized medicine and targeted drug development

Published: November 2025

Personalized drug development utilizes RNA-based therapeutics, gene therapy, and CRISPR delivery for tailored treatment of diseases. Biomimetic and nanobased systems improve drug delivery through nanocarriers, microneedle patches, and theranostic systems, while advances in cancer therapy, organ- and cell-based therapeutics, as well as diagnostic imaging and monitoring, open up new possibilities for precise and efficient therapies. Prerequisites for this are extensive pretesting and individual patient characterization. To achieve medical success, high-resolution analytics and advances in biotechnological and chemical research (novel developments in the field of drug discovery, point-of-care diagnostics, etc.) are required.

Guiding questions

  • What technological breakthroughs are needed to fully exploit biomimetic approaches in personalized medicine?
  • How can advanced technologies (e.g., CRISPR, 3D bioprinting) be integrated into existing medical infrastructures?
  • How can the economic benefits of personalized and biomimetic medicine be realized?
  • What investments are necessary to secure global competitiveness? Which actors (state vs. private) should bear these?
Image description / description: A group of people in lab coats working on a holographic screen.

Challenges

While research – especially since the complete decoding of the human genome – is making great progress, sustainable solutions for clinical practice are lacking in the field of personalized medicine. Marketable product innovations are needed, because scalability is low and the development and production of personalized medicines and therapies are not only cost-intensive but also very demanding. The high complexity is also due to the fact that expertise from biotechnology, nanotechnology and materials science must be incorporated, meaning research and development must be interdisciplinary.

Concrete examples

  • 3D-printed organs, tissues, and implants (Biocompatible materials)
  • Nanobots for drug delivery and timed release
  • Organoids for drug testing
  • Cell therapies (CAR-T cells)
  • Biomimetic support structures
  • Biomimetic Neuroprostheses
Bildbeschreibung / description: Foresight – Thuringia, Blue Eye in Focus

Foresight Report

Download

Reference

Your contacts

Reference

Michel Reichardt

Michel Reichardt Project Manager Strategic Foresight

Christoph Grollman

Christoph Grollman Project Manager Strategic Foresight

Dr. Sophia Gänßle

Dr. Sophia Gänßle Project Manager Data Science Strategic Foresight

[linguise]
Service
Top menu
Legal